Based on the heterodimeric Fc variant KiHss-AkKh, we then constructed a bsAb, termed KN026, targeting two distinct epitopes on HER2 derived from trastuzumab and pertuzumab, which are in clinical usage for the treatment of various cancers (Figure 3A). This evidence concerns the gene ERBB2 and cancer.